Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Rexulti precio?

See the DrugPatentWatch profile for Rexulti

Determining the precise price of Rexulti (brexpiprazole) can be complex, as it varies based on several factors, including insurance coverage, pharmacy, and dosage. For instance, a 30-day supply of Rexulti 1 mg tablets could cost around $500 without insurance [1]. However, with a manufacturer coupon or patient assistance program, the out-of-pocket cost might be reduced to as little as $10 per prescription [1].

How much does Rexulti cost with insurance?


Insurance plans significantly impact the final cost of Rexulti. Many insurance providers cover part of the expense, but patients may still face a co-pay. This co-pay can range from tens to hundreds of dollars per month, depending on the specific plan's formulary and deductible. It is advisable for patients to contact their insurance provider directly to understand their out-of-pocket expenses for Rexulti.

Can I get a Rexulti discount or coupon?


Yes, discounts and coupons are available for Rexulti. The manufacturer, Otsuka Pharmaceutical, offers a Rexulti Savings Card that can lower the out-of-pocket cost for eligible commercially insured patients. This card can bring the cost down to as little as $10 for a 30-day supply [1]. Eligibility requirements and program terms apply, and these cards are not available for patients with government-provided insurance, such as Medicare or Medicaid.

What is the cost of Rexulti without insurance?


Without insurance, the retail price for Rexulti can be substantial. A 30-day supply of Rexulti 1 mg tablets, for example, may cost approximately $500 [1]. This price can fluctuate between different pharmacies and may also depend on the specific dosage and quantity prescribed.

How does Rexulti's price compare to other medications for schizophrenia or depression?


Rexulti is an atypical antipsychotic used to treat schizophrenia and as an adjunctive treatment for major depressive disorder. Its pricing is generally in line with other newer atypical antipsychotics on the market. Medications like Abilify (aripiprazole), which shares a similar mechanism of action, can also have significant costs, though generic versions may be available at lower prices. Direct price comparisons are challenging due to the varying insurance coverage and discount programs applicable to each drug.

When does Rexulti's patent expire?


The patent landscape for Rexulti is complex, involving multiple patents covering the drug and its uses. Information from DrugPatentWatch.com indicates that patents related to Rexulti have expiration dates that extend into the future. For example, some patents could expire around 2030 [2]. However, patent challenges and the potential for generic entry are dynamic, and exact expiration dates for market exclusivity can be subject to legal proceedings.

What are the risks of Rexulti?


Rexulti carries several potential risks and side effects. Common side effects include akathisia (restlessness), weight gain, headache, and insomnia [3]. More serious risks include tardive dyskinesia, a movement disorder that can be irreversible, and neuroleptic malignant syndrome, a rare but potentially fatal condition characterized by fever, muscle stiffness, and altered mental status [3]. It is also associated with an increased risk of death in elderly patients with dementia-related psychosis.

What is the mechanism of action for Rexulti?


Rexulti is a partial agonist at central serotonin 5-HT1A and serotonin 5-HT2A receptors and an antagonist at serotonin 5-HT2A receptors. It also exhibits antagonist activity at noradrenergic receptors. This complex receptor binding profile is believed to contribute to its therapeutic effects in treating schizophrenia and depression [3].

How is Rexulti prescribed and what dosages are available?


Rexulti is available in oral tablet form and is typically prescribed once daily. Dosing varies depending on the condition being treated. For schizophrenia in adults, the recommended starting dose is 1 mg once daily, with titration to 2 mg or 3 mg once daily [3]. For adjunctive treatment of major depressive disorder in adults, the starting dose is 0.5 mg once daily, with titration to 1 mg or 2 mg once daily [3].

What is the current research or clinical data on Rexulti?


Clinical trials have demonstrated Rexulti's efficacy in treating symptoms of schizophrenia and as an add-on therapy for major depressive disorder. Studies have shown significant improvements in symptom scores compared to placebo in patients with schizophrenia [3]. In depression studies, Rexulti as an adjunct to standard antidepressants has led to statistically significant reductions in depression symptom scores [3]. Ongoing research may explore its potential in other psychiatric conditions.

Can I get Rexulti samples?


Physician samples of Rexulti may be available through healthcare providers. Doctors can often obtain samples from pharmaceutical representatives to provide to patients for initial trial or if financial assistance is a concern. Patients should discuss this possibility with their prescribing physician.

Sources:
[1] https://www.singlecare.com/prescription/rexulti
[2] https://www.drugpatentwatch.com/
[3] https://www.rexulti.com/



Other Questions About Rexulti :

rexulti 2023 sales u.s. Rexulti side effects? Rexulti patent expiration? Rexulti launch date? Rexulti 2023 net sales us? Rexulti approval date? Rexulti pharmaceutical company access affordability evaluation?

AI-Drug Label Prescribing Information Alignment Report

28
28%
Grade D

Poor

Not Aligned

Patient Risk: Moderate

Summary

Substantial portions of the claims are not supported by the provided FDA label excerpts (notably pricing/coupons/savings card, patent expiration, several adverse-effect items, and schizophrenia dosing/efficacy details). Some safety and mechanism claims are supported, but unsupported/non-label content is extensive.


Category Scores

Indication
85
Good
Dosage
55
Partial
Warnings
72
Partial
SpecificPopulations
70
Partial
AdverseReactions
30
Poor
Administration
60
Partial

Accurate Statements

Rexulti is an atypical antipsychotic indicated for treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
Supported by Indications and Usage.
Rexulti is indicated as adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults.
Supported by Indications and Usage.
Rexulti carries a risk of tardive dyskinesia.
Supported by Warnings and Precautions (Tardive Dyskinesia).
Tardive dyskinesia associated with Rexulti can be irreversible.
Supported by Warnings and Precautions (Tardive Dyskinesia: potentially irreversible).
Rexulti carries a risk of neuroleptic malignant syndrome (NMS).
Supported by Warnings and Precautions (NMS).
Rexulti is associated with an increased risk of death in elderly patients with dementia-related psychosis.
Supported by Warnings and Precautions (Increased Mortality in Elderly Patients with Dementia-Related Psychosis).
Rexulti is a partial agonist at central serotonin 5-HT1A receptors.
Supported by Mechanism of Action.
Rexulti is an antagonist at serotonin 5-HT2A receptors.
Supported by Mechanism of Action.
For adjunctive treatment of MDD in adults, the recommended starting dosage is 0.5 mg or 1 mg orally once daily; titrate to 1 mg once daily, then to target 2 mg once daily; maximum 3 mg/day; increase at weekly intervals.
Supported by Dosage and Administration (2.2).
Clinical trials demonstrated Rexulti as adjunctive therapy for MDD with statistically significant reductions in depression symptom scores (MADRS vs placebo + ADT).
Supported by Clinical Studies (14.1; superiority and placebo-subtracted differences).
Rexulti is dosed orally once daily for MDD adjunctive treatment.
Supported by Dosage and Administration (2.2: orally once daily).

Unsupported Statements

Rexulti pricing varies based on insurance coverage, pharmacy, and dosage.
Provided label excerpts contain no pricing, cost, or reimbursement information.
A 30-day supply of Rexulti 1 mg tablets could cost around $500 without insurance.
No cash price or dollar-cost claim is present in provided label excerpts.
A manufacturer coupon or patient assistance program may reduce out-of-pocket cost to as little as $10 per prescription for eligible patients.
No coupon/patient assistance program or $10 claim is present in provided label excerpts.
Insurance plans significantly impact the final cost of Rexulti.
No insurance/cost impact statements are present in provided label excerpts.
Patients may still face a co-pay for Rexulti despite insurance coverage.
No copay/deductible statements are present in provided label excerpts.
The co-pay for Rexulti can range from tens to hundreds of dollars per month depending on the specific plan's formulary and deductible.
No copay ranges or formulary/deductible information is present in provided label excerpts.
The manufacturer Otsuka Pharmaceutical offers a Rexulti Savings Card.
No savings card or manufacturer program information is present in provided label excerpts.
The Rexulti Savings Card can lower out-of-pocket cost for eligible commercially insured patients.
No savings card/out-of-pocket reduction eligibility statements are present in provided label excerpts.
The Rexulti Savings Card can bring the cost down to as little as $10 for a 30-day supply.
No savings card terms or $10/30-day cost claim is present in provided label excerpts.
Rexulti Savings Card is not available for patients with government-provided insurance such as Medicare or Medicaid.
No eligibility restrictions for savings cards (Medicare/Medicaid) are present in provided label excerpts.
Patents related to Rexulti have expiration dates that extend into the future.
No patent information is present in provided label excerpts.
Some Rexulti-related patents could expire around 2030.
No patent timing/expiration information is present in provided label excerpts.
Common side effects of Rexulti include akathisia (restlessness).
The provided label excerpts do not list akathisia as a common adverse reaction.
Common side effects of Rexulti include weight gain.
The provided label excerpts do not list weight gain as a common adverse reaction.
Common side effects of Rexulti include headache.
The provided label excerpts do not list headache as a common adverse reaction.
Common side effects of Rexulti include insomnia.
The provided label excerpts do not list insomnia as a common adverse reaction.
Rexulti exhibits antagonist activity at noradrenergic receptors.
Mechanism of Action excerpt provided does not state noradrenergic receptor antagonist activity.
Rexulti is prescribed orally in tablet form.
Provided label excerpts support oral dosing, but do not explicitly confirm tablet formulation.
For schizophrenia in adults, the recommended starting dose of Rexulti is 1 mg once daily.
Schizophrenia dosing details (2.3) are not included in the provided label excerpts.
For schizophrenia in adults, Rexulti dosing may be titrated to 2 mg or 3 mg once daily.
Schizophrenia dosing details (2.3) are not included in the provided label excerpts.
Clinical trials have demonstrated Rexulti's efficacy in treating symptoms of schizophrenia.
Schizophrenia clinical study results (14.2) are not included in the provided label excerpts.
In schizophrenia, Rexulti improved symptom scores compared to placebo.
Schizophrenia efficacy outcomes are not included in the provided label excerpts.
Physician samples of Rexulti may be available through healthcare providers.
No sample-availability information is present in the provided label excerpts.

Contradictions


Important Omissions

Contraindications, boxed-warning scope beyond dementia-related psychosis, and other warnings/precautions (e.g., suicidal thoughts/behaviors, metabolic changes, etc.) were not evaluated because the claim set did not address them.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported non-label claims about pricing/coupons/savings cards and several adverse-effect items could mislead stakeholders. Some safety-relevant warnings (NMS, tardive dyskinesia, increased mortality in elderly with dementia-related psychosis) are correctly reflected, but the overall label alignment is poor.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Large portion of claims (pricing/coupons/savings card, patent expiration, several 'common side effects', schizophrenia dosing/efficacy, receptor activity) are not supported by the provided FDA label excerpts.

Suggested Improvement
Limit statements strictly to label-supported content from the provided sections; remove pricing/coupon/patent-related claims and any adverse-effect or receptor-activity statements not explicitly supported by the included label excerpts.

Drug Brand Mention Assessment

Branding Score
58
Visibility
64
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Price varies based on factors like insurance coverage, pharmacy, and dosage
  • A 30-day supply of Rexulti 1 mg tablets could cost around $500 without insurance
  • With a manufacturer coupon or patient assistance, out-of-pocket cost might be reduced to as little as $10
  • Rexulti is an atypical antipsychotic used to treat schizophrenia and as an adjunctive treatment for major depressive disorder
  • Rexulti carries potential risks and side effects including akathisia and weight gain
Differentiators

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Abilify 43%
50 #5 No